241 related articles for article (PubMed ID: 32927719)
1. Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.
Gozzetti A; Raspadori D; Bacchiarri F; Sicuranza A; Pacelli P; Ferrigno I; Tocci D; Bocchia M
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32927719
[TBL] [Abstract][Full Text] [Related]
2. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
Oliva S; D'Agostino M; Boccadoro M; Larocca A
Front Oncol; 2020; 10():1. PubMed ID: 32076595
[TBL] [Abstract][Full Text] [Related]
3. "Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.
Pacelli P; Raspadori D; Bestoso E; Gozzetti A; Bocchia M
Front Oncol; 2022; 12():1057713. PubMed ID: 36518304
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
[No Abstract] [Full Text] [Related]
5. Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy.
Krishnan A; Vij R; Keller J; Dhakal B; Hari P
Am Soc Clin Oncol Educ Book; 2016; 35():210-21. PubMed ID: 27249701
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation.
Takamatsu H
J Clin Med; 2017 Sep; 6(10):. PubMed ID: 28946710
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance and minimal residual disease in multiple myeloma.
Gozzetti A; Ciofini S; Sicuranza A; Pacelli P; Raspadori D; Cencini E; Tocci D; Bocchia M
Cancer Drug Resist; 2022; 5(1):171-183. PubMed ID: 35582527
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
12. Steps towards a Multiple Myeloma Cure?
Gozzetti A; Bocchia M
J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143236
[TBL] [Abstract][Full Text] [Related]
13. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
15. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
Paiva B; Puig N; García-Sanz R; San Miguel JF;
Clin Cancer Res; 2015 May; 21(9):2001-8. PubMed ID: 25754350
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli N; Genuardi E; Ziccheddu B; Martello M; Oliva S; Terragna C
Front Oncol; 2020; 10():189. PubMed ID: 32181154
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.
Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R
Front Oncol; 2019; 9():726. PubMed ID: 31448230
[No Abstract] [Full Text] [Related]
19. [Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2018; 59(10):2153-2161. PubMed ID: 30305521
[TBL] [Abstract][Full Text] [Related]
20. [Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease].
Solovyev MV; Mendeleeva LP; Pokrovskaya OS; Nareyko MV; Firsova MV; Galtseva IV; Davydova YO; Kapranov NM; Kuzmina LA; Gemdzhian EG; Savchenko VG
Ter Arkh; 2017; 89(7):25-31. PubMed ID: 28766537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
